Amphenol Q1 Revenues Jump 58.4% to $7.62B, Barclays Boosts Target to $180
Amphenol reported first-quarter revenues of $7.62 billion, up 58.4% year-over-year, with adjusted EPS rising 68.3% to $1.06 and record orders of $9.4 billion. Barclays lifted its price target to $180 and analysts’ mean estimates imply a 27.7% upside, while second-quarter sales are guided between $8.1 billion and $8.2 billion and net debt stands at $14.2 billion.
1. Record First-Quarter Financials
Amphenol delivered $7.62 billion in first-quarter revenue, marking a 58.4% year-over-year increase, and posted adjusted EPS of $1.06, up 68.3%. Strong performance in the AI data center and IT datacom markets drove organic growth of 33% and record quarterly orders totaling $9.4 billion.
2. Analyst Price Targets and Upside
Analysts’ average price targets imply a 27.7% upside for the stock, reflecting consensus on rising earnings estimates. Barclays raised its target from $175 to $180 and maintained an overweight rating, signaling confidence in continued outperformance.
3. Q2 Guidance and Balance Sheet Health
Management projects second-quarter sales between $8.1 billion and $8.2 billion, supported by ongoing AI data center demand. Net debt stands at $14.2 billion with leverage under two times EBITDA, indicating a well-managed balance sheet relative to earnings.